The new Internal Revenue Code Section 4191 imposes a 2.3% excise tax on sales of any "taxable medical device" by the manufacturer, producer, or importer of the device. As a provision of the Affordable Care Act of 2010, Section 4191 is one of several revenue-raisers intended to offset the costs of broadening U.S. health care coverage.
Beginning on January 1, 2013, medical device sales will be subject to the new tax. The problem is, preparing for compliance with medical device excise tax (MDET) requirements will be a complex undertaking for many companies.
Deloitte's MDET Services (MDETS) is a dedicated national team of professionals specializing in disciplines that can help you address the many challenges associated with these requirements.
Download Medical Device Excise Tax Services: A structured approach to January 1, 2013 readiness PDF to learn more.
As used in this document, “Deloitte” means Deloitte Tax LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.